Zetia Cost in Tennessee 2026: Cash Price, Medicaid Coverage, and Savings Options

What Does Zetia Actually Cost in Tennessee in 2026?

The brand-name Zetia carries a manufacturer list price near $380 per month, but almost no cash-pay patient in Tennessee needs to pay that figure. Generic ezetimibe 10 mg is available at major Tennessee retail chains, including Walmart, Kroger, and CVS, for roughly $15 per month without insurance. GoodRx and similar discount platforms frequently show prices between $9 and $18 depending on pharmacy location and coupon applied.

The gap between brand and generic pricing exists because ezetimibe lost patent exclusivity and multiple generic manufacturers now supply the market. The FDA's Orange Book lists more than a dozen approved generic ezetimibe products as of 2025 [1]. A Tennessee patient filling a 90-day supply at a warehouse pharmacy such as Costco may pay as little as $20 to $25 for three months, which is $7 to $8 per month.

Brand-name Zetia still carries that $380 list price because Merck maintains a manufacturer savings card. Eligible commercially insured patients may pay as little as $5 per month with the card, but TennCare and Medicare Part D patients are excluded from manufacturer coupon programs under federal anti-kickback rules. For those populations, the generic is the straightforward path to affordability.

Tennessee has 95 counties served by an extensive network of independent and chain pharmacies. Prices within the same city can vary by $4 to $6 even for the same generic, so calling ahead or using a real-time comparison tool before filling remains the fastest way to find the lowest local price [2].

Does TennCare (Tennessee Medicaid) Cover Zetia or Ezetimibe?

TennCare covers generic ezetimibe, but only for enrollees who carry a diagnosis of type 2 diabetes. Standard hyperlipidemia alone does not meet the coverage criterion under the current TennCare preferred drug list. Patients seeking ezetimibe purely for LDL reduction without a concurrent diabetes diagnosis will need to pay cash, use a discount card, or ask their prescriber about a prior authorization appeal.

This coverage restriction is narrower than most other state Medicaid programs, which generally cover ezetimibe as a non-preferred or preferred drug on the lipid-lowering tier. Tennessee's Bureau of TennCare publishes its preferred drug list on the state website and updates it quarterly [3]. Prescribers filing a prior authorization for a non-diabetic patient with documented statin intolerance or a very high cardiovascular risk score may succeed, but approval is not guaranteed and typically requires chart documentation of at least one failed or contraindicated statin.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are judged to be very high risk and are receiving maximally tolerated statin therapy, if LDL-C remains 70 mg/dL or higher, it is reasonable to add ezetimibe to statin therapy" [4]. That guideline language supports a prior authorization argument, but TennCare's formulary decisions are independent of ACC/AHA recommendations.

TennCare members on the BlueCare Tennessee, UnitedHealthcare Community Plan, or Amerigroup Tennessee managed care plans should confirm ezetimibe coverage directly with their plan, because each managed care organization may apply slightly different tier placement rules even within the TennCare benefit structure.

Which Commercial Insurance Plans Cover Zetia in Tennessee?

Most commercial insurance plans sold through the federal marketplace or employer groups in Tennessee place generic ezetimibe on Tier 1 or Tier 2, meaning a typical copay runs $10 to $45 per month. Brand-name Zetia is more often Tier 3 or Tier 4 on commercial formularies, with copays ranging from $60 to over $150 unless a prior authorization for brand-necessary treatment is approved.

BlueCross BlueShield of Tennessee, the largest commercial insurer in the state, lists generic ezetimibe as a preferred generic on most of its individual and group formularies. Cigna, Aetna, and UnitedHealthcare products sold in Tennessee follow similar Tier 1 placement for the generic. The practical implication: ask your pharmacist to substitute generic ezetimibe for brand Zetia at the point of dispensing if your prescriber wrote for the brand. Tennessee law permits generic substitution unless the prescriber writes "dispense as written" [5].

Medicare Part D plans vary significantly. The CMS formulary finder tool allows any Tennessee resident to search by zip code and compare ezetimibe coverage tiers across all available Part D plans during open enrollment. In 2025, most Part D plans placed generic ezetimibe at $0 to $10 per month after the Inflation Reduction Act cap changes took effect for certain drug categories, though ezetimibe is not on the $35 insulin cap list specifically.

The HealthRX Tennessee Ezetimibe Access Decision Framework:

1. Commercial insurance: Request generic substitution; expect Tier 1 copay of $10 to $45.
2. TennCare with T2D diagnosis: Covered; fill generic at network pharmacy.
3. TennCare without T2D: Submit prior authorization with ASCVD risk documentation and statin intolerance records.
4. Medicare Part D: Compare plans at cms.gov formulary finder; most list generic at $0 to $10.
5. Uninsured or underinsured: Use GoodRx or Mark Cuban's Cost Plus Drugs (ezetimibe listed at approximately $8 for 30 tablets as of mid-2025); or request a 503A compounded formulation.

Is Compounded Ezetimibe Legal in Tennessee?

Yes. Licensed 503A compounding pharmacies operating in Tennessee may prepare compounded ezetimibe for individual patients when a valid patient-specific prescription exists. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, and Tennessee state pharmacy law does not add a blanket prohibition on compounding ezetimibe [6].

The distinction between 503A and 503B matters here. A 503A pharmacy fills individual prescriptions compounded for a specific named patient. A 503B outsourcing facility produces larger batches and supplies healthcare providers. Compounded ezetimibe for individual patients in Tennessee flows through 503A pharmacies. Some telehealth platforms have structured programs where compounded ezetimibe is included in a broader cardiometabolic treatment package at little or no incremental cost to the patient, which is why some sources list the compounded price as $0 per month.

The FDA has not placed ezetimibe on its list of drugs that may not be compounded (the "Category 1" list), so 503A compounding remains permitted under current federal guidance [7]. Patients and prescribers should confirm that any compounding pharmacy they use holds a current Tennessee Board of Pharmacy license before filling.

One caveat: compounded ezetimibe has not been tested in the same large randomized controlled trials as the FDA-approved tablet. The clinical evidence base, including IMPROVE-IT, used the approved formulation. Bioequivalence data for compounded versions are not publicly available in the same way as for FDA-approved generics.

The Clinical Case for Ezetimibe: What the Evidence Shows

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50% and lowering LDL cholesterol by 18 to 25% as monotherapy [8]. Added to a statin, it produces an additional 23 to 24% LDL reduction on top of what the statin achieves alone [9].

The landmark IMPROVE-IT trial (N=18,144) enrolled patients after acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. After a median follow-up of 6 years, the combination arm achieved a mean LDL of 53.7 mg/dL versus 69.5 mg/dL in the statin-only arm. The primary endpoint, a composite of cardiovascular death, major coronary events, and stroke, occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group, an absolute risk reduction of 2.0 percentage points and a relative risk reduction of 6.4% (P<0.001) [10].

The trial enrolled over 7 years and the benefit grew larger with longer treatment duration, consistent with the concept that LDL lowering is cumulative over time. The ACC/AHA 2018 cholesterol guideline cited IMPROVE-IT directly when recommending ezetimibe as the first add-on agent after maximally tolerated statin therapy in very-high-risk ASCVD patients [4].

Ezetimibe is generally well tolerated. Myopathy rates in IMPROVE-IT were no higher than placebo. Hepatic enzyme elevations above three times the upper limit of normal occurred in fewer than 1% of participants. The drug carries no dose-response relationship in the traditional sense because it is approved as a single 10 mg dose; there is no 5 mg or 20 mg approved strength for LDL titration [1].

For Tennessee patients who are statin-intolerant and not yet candidates for PCSK9 inhibitors (which cost $500 to $700 per month even with rebates), ezetimibe at $15 per month cash represents the most accessible evidence-backed LDL-lowering option on the market.

How to Get Ezetimibe via Telehealth in Tennessee

Tennessee law permits telehealth prescribing of ezetimibe. The state's telehealth statutes require that a valid prescriber-patient relationship be established before a controlled substance is issued, but ezetimibe is not a controlled substance, so that restriction does not apply [11]. A licensed Tennessee prescriber may conduct a synchronous audio-video visit, review a patient's lipid panel and cardiovascular history, and issue a valid ezetimibe prescription in a single encounter.

Several national telehealth platforms with Tennessee-licensed prescribers offer cardiometabolic programs that include ezetimibe prescribing. The prescription may be sent to any Tennessee retail pharmacy or, in programs that include compounded ezetimibe, to a partner 503A compounding pharmacy.

Patients should bring a recent lipid panel (ideally within 12 months) to the telehealth visit. A fasting lipid panel showing LDL 70 mg/dL or above in a patient with established ASCVD, or LDL 100 mg/dL or above in a patient with diabetes or 10-year ASCVD risk above 7.5%, provides the clinical context a prescriber needs to start ezetimibe per guideline recommendations [4].

After starting ezetimibe, the ACC/AHA guideline recommends a fasting lipid panel at 4 to 12 weeks to assess response and confirm adherence [4]. Most telehealth platforms can order lab work through national reference labs, and several Tennessee LabCorp and Quest locations offer self-pay lipid panels for $25 to $40.

Tennessee-Specific Drug Assistance and Discount Programs

Several programs are available to Tennessee residents who cannot afford ezetimibe even at the $15 generic price point.

Merck's patient assistance program covers brand-name Zetia for uninsured patients below certain income thresholds. The application requires proof of Tennessee residency, income documentation, and a prescriber signature. Processing typically takes two to four weeks [12].

The RxAssist database lists additional Tennessee-specific pharmaceutical assistance programs that independent social workers at hospital systems including Vanderbilt University Medical Center, the University of Tennessee Medical Center, and Regional One Health use to connect patients with free or low-cost medications.

Tennessee's State Health Insurance Assistance Program (SHIP) provides free counseling to Medicare beneficiaries on Part D plan selection, which directly affects ezetimibe out-of-pocket costs for patients over 65.

GoodRx Gold membership ($9.99 per month) provides a flat-rate discount at most Tennessee pharmacies and may reduce the generic ezetimibe price to $8 to $12, which covers the membership cost if the patient fills even one generic prescription monthly.

Ezetimibe Dosing, Drug Interactions, and What Tennessee Prescribers Monitor

The approved dose is ezetimibe 10 mg orally once daily, taken with or without food, at any time of day. No renal dose adjustment is needed. Hepatic impairment (Child-Pugh B or C) is a contraindication because ezetimibe undergoes extensive hepatic glucuronidation [1].

The most clinically relevant drug interaction in Tennessee's patient population is the combination with fibrates, particularly gemfibrozil. Co-administration increases ezetimibe plasma levels approximately 1.5-fold and raises cholecystolithiasis risk. Fenofibrate is preferred over gemfibrozil when a fibrate is needed alongside ezetimibe [8].

Cyclosporine markedly increases ezetimibe exposure (approximately 3.4-fold). Tennessee transplant patients on cyclosporine who receive ezetimibe should have LFTs and ezetimibe response monitored more closely. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55% and should be dosed at least two hours before or four hours after ezetimibe [1].

Prescribers in Tennessee initiate a baseline lipid panel and ALT before starting therapy. Because isolated ezetimibe hepatotoxicity is rare and the drug does not require routine liver function monitoring in the same way statins did under older labeling, most guidelines recommend monitoring only if symptoms suggest hepatic dysfunction [4].